Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
- Autores
- Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; Luna, J. D.
- Año de publicación
- 2015
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.
Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
Fil: Marquez, G. E.. Fundacion Ver; Argentina
Fil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina
Fil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
Fil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Luna, J. D.. Fundacion Ver; Argentina - Materia
-
Central Serous Chorioretinopathy
Melatonin
Optical Coherence Tomography (Oct)
Fluorescein Angiography - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/14003
Ver los metadatos del registro completo
id |
CONICETDig_b78cb236976de6f7a5a6d524f1d956a6 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/14003 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathyGramajo, Ana LauraMarquez, G. E.Torres, Victor Eduardo RoqueJuarez, Cecilia PaolaRosenstein, Ruth EstelaLuna, J. D.Central Serous ChorioretinopathyMelatoninOptical Coherence Tomography (Oct)Fluorescein Angiographyhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; ArgentinaFil: Marquez, G. E.. Fundacion Ver; ArgentinaFil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; ArgentinaFil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; ArgentinaFil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaFil: Luna, J. D.. Fundacion Ver; ArgentinaNature Publishing Group2015-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/14003Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-10450950-222X1476-5454enginfo:eu-repo/semantics/altIdentifier/url/http://www.nature.com/eye/journal/v29/n8/full/eye2015104a.htmlinfo:eu-repo/semantics/altIdentifier/doi/10.1038/eye.2015.104info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541344/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:58:06Zoai:ri.conicet.gov.ar:11336/14003instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:58:06.997CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
title |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
spellingShingle |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy Gramajo, Ana Laura Central Serous Chorioretinopathy Melatonin Optical Coherence Tomography (Oct) Fluorescein Angiography |
title_short |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
title_full |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
title_fullStr |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
title_full_unstemmed |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
title_sort |
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy |
dc.creator.none.fl_str_mv |
Gramajo, Ana Laura Marquez, G. E. Torres, Victor Eduardo Roque Juarez, Cecilia Paola Rosenstein, Ruth Estela Luna, J. D. |
author |
Gramajo, Ana Laura |
author_facet |
Gramajo, Ana Laura Marquez, G. E. Torres, Victor Eduardo Roque Juarez, Cecilia Paola Rosenstein, Ruth Estela Luna, J. D. |
author_role |
author |
author2 |
Marquez, G. E. Torres, Victor Eduardo Roque Juarez, Cecilia Paola Rosenstein, Ruth Estela Luna, J. D. |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
Central Serous Chorioretinopathy Melatonin Optical Coherence Tomography (Oct) Fluorescein Angiography |
topic |
Central Serous Chorioretinopathy Melatonin Optical Coherence Tomography (Oct) Fluorescein Angiography |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable. Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina Fil: Marquez, G. E.. Fundacion Ver; Argentina Fil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina Fil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina Fil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina Fil: Luna, J. D.. Fundacion Ver; Argentina |
description |
PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-08 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/14003 Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-1045 0950-222X 1476-5454 |
url |
http://hdl.handle.net/11336/14003 |
identifier_str_mv |
Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-1045 0950-222X 1476-5454 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.nature.com/eye/journal/v29/n8/full/eye2015104a.html info:eu-repo/semantics/altIdentifier/doi/10.1038/eye.2015.104 info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541344/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Nature Publishing Group |
publisher.none.fl_str_mv |
Nature Publishing Group |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613734031425536 |
score |
13.070432 |